CG Oncology, Inc. Common stock
CGON · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1 | $0 | $0 | $10 |
| % Growth | 458.3% | 6.8% | -98.2% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $1 | $0 | $0 | $10 |
| % Margin | 100% | 100% | 92.1% | 99.9% |
| R&D Expenses | $82 | $46 | $29 | $18 |
| G&A Expenses | $34 | $10 | $6 | $5 |
| SG&A Expenses | $34 | $10 | $6 | $5 |
| Sales & Mktg Exp. | $0 | $0 | -$0 | -$0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $116 | $56 | $35 | $23 |
| Operating Income | -$115 | -$55 | -$35 | -$13 |
| % Margin | -10,067.3% | -27,180.9% | -18,453.4% | -121.7% |
| Other Income/Exp. Net | $27 | $7 | -$0 | -$0 |
| Pre-Tax Income | -$88 | -$49 | -$35 | -$13 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$88 | -$49 | -$35 | -$13 |
| % Margin | -7,729.5% | -23,827% | -18,556.5% | -124% |
| EPS | -1.41 | -1.02 | -0.66 | -0.28 |
| % Growth | -38.2% | -54.5% | -135.7% | – |
| EPS Diluted | -1.41 | -1.02 | -0.66 | -0.28 |
| Weighted Avg Shares Out | 62 | 67 | 67 | 67 |
| Weighted Avg Shares Out Dil | 62 | 67 | 67 | 67 |
| Supplemental Information | – | – | – | – |
| Interest Income | $27 | $7 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$115 | -$55 | -$35 | -$12 |
| % Margin | -10,064.4% | -27,172.5% | -18,445.5% | -119.5% |